IP Library Granted Patent US 8,106,015
Granted Patent B2
US 8,106,015 · App. 12/596,741 · Granted Jan 31, 2012

Method for enhancing immune response with peptide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,015
App. No.
12/596,741
Granted
Jan 31, 2012
Kind
B2
Abstract

An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.

Claims (21)

1. An immunogenic peptide that induces an enhanced immune response comprising an amyloid β peptide or an amyloid β peptide fragment which comprises at least the 1st-28th amino acid residues of an amino acid sequence of the amyloid β peptide with the insertion of cysteine into the amyloid β peptide or the amyloid β peptide fragment between the 18th and 19th amino acid residues, between the 25th and 26th amino acid residues, or between the 28th and 29th amino acid residues, wherein the residues are counted from the N-terminus of the amyloid β peptide or the amyloid β peptide fragment.

2. The immunogenic peptide according to claim 1 , wherein the amyloid β peptide or the amyloid β peptide fragment is an amyloid β peptide consisting of the amino acid sequence of SEQ ID NO: 34 or an amyloid β peptide fragment which comprises at least the 1st-28th amino acid residues of SEQ ID NO:34.

3. The immunogenic peptide according to claim 1 , which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52.

4. The immunogenic peptide according to claim 1 , which consists of the amino acid sequence of SEQ ID NO: 46.

5. The immunogenic peptide according to claim 1 , which consists of the amino acid sequence of SEQ ID NO: 48.

6. The immunogenic peptide according to claim 1 , which consists of the amino acid sequence of SEQ ID NO: 50.

7. The immunogenic peptide according to claim 1 , which consists of the amino acid sequence of SEQ ID NO: 52.

8. A medicament comprising the immunogenic peptide of claim 1 as an active ingredient, and a pharmaceutically acceptable excipient.

9. A medicament comprising the immunogenic peptide of claim 1 as an active ingredient, a pharmaceutically acceptable excipient, and an adjuvant.

10. A medicament comprising the immunogenic peptide of claim 1 as an active ingredient, and a pharmaceutically acceptable excipient, with the proviso that the medicament does not contain an adjuvant.

11. A medicament comprising the immunogenic peptide of claim 3 as an active ingredient, and a pharmaceutically acceptable excipient.

12. A medicament comprising the immunogenic peptide of claim 3 as an active ingredient, a pharmaceutically acceptable excipient, and an adjuvant.

13. A medicament comprising the immunogenic peptide of claim 3 as an active ingredient, and a pharmaceutically acceptable excipient, with the proviso that the medicament does not contain an adjuvant.

14. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the immunogenic peptide of claim 1 .

15. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the immunogenic peptide of claim 3 .

16. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 8 .

17. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 9 .

18. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 10 .

19. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 11 .

20. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 12 .

21. A method of treating Alzheimer disease, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the medicament of claim 13 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2009
From: MATSUDA, JUNICHI; KAMINAKA, KAZUYOSHI; NOZAKI, CHIKATERU
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 023411/0175 →